Work

OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study

Year: 2021
Type: conference-abstract
Abstract: Rationale: Severe asthma is frequently associated with comorbidities.Nasal polyps (NP), in particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced response to benralizumab in terms of asthma exacerbations and lung function.Increased serum immunoglobulin (Ig) E levels and atopy are also common in severe asthma, although they tend not to be associated with increased risk of exacerbations or predict response to biologics.Benralizumab has been shown to decrease long-term oral corticosteroid (OCS) use among patients with severe asthma, but whether the presence of comorbid NP, elevated serum IgE, or the presence of atopy impacts the degree of OCS reduction achieved with benralizumab is unknown.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3160881399
Cites:
Cited by:
Related to: 10